TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
HOLD

Pfizer Inc(PFE)

Mar 02, 2023

Going into slower growth, defensive stocks like those in healthcare tend to do very well. Benefited incredibly from Covid. Great business. Used to be much more broad-based, but sold them all off. Drugs take a long time to produce. Great dividend yield.

Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$40.35

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Pfizer Inc(PFE)

Feb 28, 2023
Stockchase Research Editor: Michael O’Reilly

We reiterate PFE as a TOP PICK.  With a ROE of 36% and trading at 7x earnings this is good value here.  The company expects to hear soon if its RSV vaccine will get approval as one of the first available for people over 60 years of age.  Cash reserves continue growing while the company retires debt. It pays a nice dividend, backed by a payout ratio un 30% of cash flow.  We continue to recommend a stop-loss at $35, looking to achieve $52.50 - upside potential over 28%.  Yield 3.9%

(Analysts’ price target is $52.52)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$40.57

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 14, 2023

Good cash flow and pays a 3.7x dividend. Cheap at 12x PE. Good cardio drug in the pipeline, looking promising. Shares are down lately because of a general rotation and society is getting indifferent to Covid and vaccines. Management sees 7-9% revenue growth outside Covid vaccines. Strong balance sheet. Offers defence and offence.

Photo of Stan WongStan Wong
Owned
Unlock Rating
$43.90

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 27, 2023
It reports Tuesday. The street doesn't like it, because of the performance of PFE's Covid vaccines. He disagrees--there's much more to Pfizer than the street thinks.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$43.79

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 24, 2023
Healthcare is weak at the start of each year. Pfizer chart shows lower lows and lower highs. Doesn't see a strong seasonal pattern for Pfizer now. Things pick up in May/June for healthcare.
Photo of Brooke ThackrayBrooke ThackrayUnlock Rating
$44.66

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 23, 2023
The drug space is a difficult one to be in so he doesn't own stocks in that space. It did a massive business with the vaccine. Now it will have to spend a lot of cash to make acquisitions since the base business for the big pharmaceuticals is flattening.
Photo of Lorne SteinbergLorne Steinberg
No
Unlock Rating
$44.98

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Pfizer Inc(PFE)

Jan 19, 2023
Stockchase Research Editor: Michael O'Reilly Following on its mRNA success with the COVID vaccine, PFE is advancing an RSV vaccine candidate that stimulated an immune response in pregnant women -- key to reduce RSV infection that impacts 125,000 infants in the US annually. The stock trades at only 9x earnings and 2.7x book. Recently reported earnings support a ROE of 35% and the company has been aggressively retiring debt. We recommend a stop-loss at $35, looking to achieve $55.50 -- upside potential over 22%. Yield 0% (Analysts’ price target is $55.49)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$44.96

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jan 18, 2023
It's been downgraded and shares have gone down. It's cheap enough now. Buy some now and buy more if the dividend rises back to 4% (at 3.6% now). Their pipeline looks promising.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$45.00

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 12, 2023
(A Top Pick Jan 12/22, Down 15%) 11x forward PE. Outperforming S&P since early 2021. Healthy drug pipeline. Still sees 30B USD in sales for Covid vaccines and treatment. Defensive and steady growth. Weak relative to market in January, an opportunity. Yield is 3.5%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$47.48

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 09, 2022
Monday they hold an analysts meeting to discuss their drug pipeline. Their biggest problem is that the street thinks there isn't much more to this company than its Covid franchise. Untrue! They've made enough acquisitions and invested in their pipeline to keep making new drugs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$51.72

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 23, 2022
Sell PFE to buy MRK? Likes and owns them both. MRK is more in the immuno oncology and cancer space, whereas PFE is more diversified. Defensive and growth characteristics. MRK hit a new high today. PFE hasn't done as well, but has performed over the last 2 years. Own both for different reasons. May want to trim in early part of next cycle. Yield is 3.3%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$48.78

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 12, 2022
It has always been part of their health care portfolio. It is losing some lustre and interest created by Covid but is still a good health care company with a good dividend. He likes others as well, maybe a bit better.
Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$47.76

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Sep 08, 2022
When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.4%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$46.79

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 01, 2022
PFE vs. JNJ Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
Photo of Jason MannJason Mann
Owned
Unlock Rating
$46.48

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 10, 2022
Always a wall of worry around drug pricing, but rarely does it have a large impact. He sold this name after record revenues from vaccine news. He likes AZN, which is getting approval after approval. Another one is LLY, focusing on its diabetes and weight loss drug.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$49.52

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 136 to 150 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like